• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Merck Is All In With a Threefold Approach to Covid-19

I've been long Merck for a long time, since way before this pandemic became part of our lives.
By STEPHEN GUILFOYLE
May 26, 2020 | 10:16 AM EDT
Stocks quotes in this article: GILD, MRNA, JNJ, PFE, NVAX, MRK, AZN

Readers know that I have been all in on the various biotechs and big pharmas that have been working on finding either vaccines and/or therapeutics related to either treating or just plain avoiding human infection with the SARS-CoV-2 coronavirus that caused the disease known as Covid-19. I have been in and out of Gilead Sciences (GILD) for some time now. I have been in and out, mostly in, on Moderna (MRNA) . I have been in Johnson & Johnson (JNJ) as well as Pfizer (PFE) . I have dabbled in Novavax (NVAX) solely through the use of options spreads without holding equity. In other words, when the scientists win this fight, I want to be on their team.

I have been long Merck (MRK) for a long time, since way before this pandemic became part of our lives. That's based on a number of candidates, or work on special cocktails meant to treat various types of cancers as well as other maladies. Just last week there was news of a collaboration between Merck and AstraZeneca (AZN) on the prostate cancer front. The stock has not, however... performed all that well this year, and on many an occasion, I really came this close >< to liquidating the position, as the firm mostly remained silent on Covid-19, and I had come close to being overexposed to the group. The silence is over.

Tuesday Morning

Not the Moody Blues song. That's not until later. Merck released an absolute plethora of news on Tuesday morning regarding the firm's efforts to take on the coronavirus. The efforts mentioned this morning are threefold, two aimed at vaccination, and one, which really catches my interest, aimed at treatment. Let's go through what we know.

One... Merck will acquire Themis Biosciences, an Austrian developer of various vaccines and immunomodulation therapies for infectious diseases, which includes work of Covid-19. This Themis program has already been under way using a modified measles virus as a vector. Phase 1 trials for this effort are expected to begin within weeks.

Two... Merck announced a collaboration with IAVI (International AIDS Vaccine Initiative) to develop a Covid-19 vaccine. This vaccine that uses the same technique that Merck used in the creation of Everbo, the firm's vaccine for Ebola. Phase 1 is expected to begin later this year for this model.

Three... Merck also announced a collaboration with Ridgeback Biotherapeutics meant to develop an antiviral candidate known as EIDD-2801. Under this deal, Merck secures exclusive global rights as well as a share of eventual proceeds. Once approved, clinical development, navigating the regulatory environment, and manufacturing to scale all become the responsibility of Merck.

The Story

Investors know that I have been touting the approach taken by both Moderna and Pfizer as I became aware of these efforts as they use newer messenger RNA technology, that even if really unproven coming in, can be developed and produced much more rapidly than vaccines reliant upon traditional means. Merck CEO Ken Frazier, who will be visible across financial media platforms on Tuesday, opened up over the weekend. He let us know that Merck's scientists have been on the job for as long as they have been aware of this coronavirus. Merck also wanted to go down the path of already proven technology, which ends up looking pretty smart from a global perspective, if the newer kind of vaccines either fail, or become less effective over time.

Frazier is quoted on the Barron's website this morning as saying, "We've got to immunize seven billion people on the planet, if you have a dose that gives you a high amount of neutralizing antibodies with a single dose, that's a much better, more simple to deploy vaccine, than one that requires multiple doses."

Now, what I find most interesting is the therapeutic effort. On this candidate, which is already in Phase 1 clinical trials, Frazier said, "We know from the work that's already done already that it's very potent, that it blocks the reproduction of many RNA viruses, including SARS-CoV-2." The best two characteristics of this treatment if approved would be that apparently the firm feels that this drug would be readily scale-able, as well as orally deliverable, which would be huge.

The Chart

Obviously, this morning's news took the shares back above their 50 day SMA, and hanging onto that level would be technically important. The vaccines are further out than some efforts being made by competitors, so those candidates are not this year's story for Merck. The therapeutic is the story here. You give perplexed doctors a choice other than Remdesivir for treating struggling patients and that market, I believe, opens wide with demand.

Readers will see that my cup with handle pattern more or less failed. What this does for me as a shareholder is take my target price down to $85, which had been the pivot. The $75 level would be important here, and that has been support. That door opens and prices could move considerably lower. That said, I would not exit this name completely ahead of more news regarding the effort with Ridgeback Biotherapeutics on EIDD-2801.

(Johnson & Johnson is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells JNJ? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long MRK, MRNA, JNJ, PFE equity.

TAGS: Drug Approvals | Investing | Stocks | Technical Analysis | Trading | Biotechnology | Pharmaceuticals | Coronavirus

More from Investing

Fear and Anxiety on Wall Street

James "Rev Shark" DePorre
Aug 17, 2022 4:41 PM EDT

We've got fear of missing out and wariness that the market may keep running away to the upside.

Peabody Is Glowing Hot

Mark Sebastian
Aug 17, 2022 3:19 PM EDT

Here's how to play Peabody Energy as it looks like it could fire up over $25.

It's Hard to Say What's Cookin' at Weber, Though It Smells Like a Short Squeeze

Jonathan Heller
Aug 17, 2022 11:30 AM EDT

The grillmaker's stock has traded wildly and heavily at times, most recently this week after it posted its latest results on Monday.

Dour Day Shows Why I've Been Raising Cash Into Strength

James "Rev Shark" DePorre
Aug 17, 2022 10:44 AM EDT

I'm not aggressively bearish, but just waiting for better technical conditions.

Target Badly Misses the Mark, Which Sets It Up for a Bearish Bet

Stephen Guilfoyle
Aug 17, 2022 10:30 AM EDT

The big retailer's second-quarter results were atrocious and so is its balance sheet, which makes it a stock not to buy right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:23 PM EDT STEPHEN GUILFOYLE

    We're Cleaning Out This Retailer From the Bullpen

    Check out the latest moves in TheStreet's Stocks U...
  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login